{"id":2485,"date":"2015-09-24T13:27:23","date_gmt":"2015-09-24T13:27:23","guid":{"rendered":"https:\/\/www.lymphoma.ca\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/"},"modified":"2015-09-24T13:27:23","modified_gmt":"2015-09-24T13:27:23","slug":"le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/","title":{"rendered":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin"},"content":{"rendered":"<p>Une \u00e9tude publi\u00e9e en juin 2015 dans le ASH Blood Journal, rapporte que le brentuximab vedotine s\u2019av\u00e8re un traitement de choix efficace et s\u00e9curitaire dans le cas de patients \u00e2g\u00e9s atteints de la maladie de Hodgkin et inaptes \u00e0 subir un traitement de chimioth\u00e9rapie.<br \/>\n<!--more--><\/p>\n<h2>Phase 2 de l\u2019\u00e9tude sur la monoth\u00e9rapie de premi\u00e8re ligne par brentuximab vedotine chez les patients, \u00e2g\u00e9s de plus de 60 ans, atteints de la maladie de Hodgkin<\/h2>\n<p>U<span style=\"line-height: 24px;\">ne \u00e9tude publi\u00e9e en juin 2015 dans le <\/span><em style=\"line-height: 24px;\">ASH Blood Journal<\/em><span style=\"line-height: 24px;\">, rapporte que le brentuximab vedotine s\u2019av\u00e8re un traitement de choix efficace et s\u00e9curitaire dans le cas de patients \u00e2g\u00e9s atteints de la maladie de Hodgkin et inaptes \u00e0 subir un traitement de chimioth\u00e9rapie.<\/span><\/p>\n<p>M\u00eame si la chimioth\u00e9rapie standard peut entra\u00eener une r\u00e9mission compl\u00e8te chez les patients plus jeunes touch\u00e9s par la maladie de Hodgkin (MH), la majorit\u00e9 des personnes de plus de 60 ans sont consid\u00e9r\u00e9es comme inadmissibles ou refusent le traitement afin d\u2019\u00e9viter les complications li\u00e9es \u00e0 la toxicit\u00e9 du m\u00e9dicament. Le taux de r\u00e9mission \u00e9tant nettement plus faible chez les patients \u00e2g\u00e9s atteints de la MH que chez les plus jeunes, il est clair qu\u2019il faut trouver des traitements moins toxiques permettant aux patients de plus de 60 ans de terminer leur programme de traitement sans complication et sans interruption. Selon plusieurs chercheurs, l\u2019un des traitements prometteurs est le brentuximab vedotine, une th\u00e9rapie qui cible les cellules de la MH et permet de d\u00e9livrer des doses puissantes de chimioth\u00e9rapie sans nuire aux cellules saines. Lors d\u2019\u00e9tudes ant\u00e9rieures, le brentuximab vedotine a entra\u00een\u00e9 une r\u00e9mission chez des patients atteints d\u2019une MH r\u00e9cidivante ou d\u2019une MH r\u00e9fractaire au traitement.<\/p>\n<p>Blood Journal &#8211; <a href=\"http:\/\/www.bloodjournal.org\/content\/early\/2015\/09\/16\/blood-2015-06-644336?sso-checked=true\">Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older<\/a><\/p>\n<p>EurekAlert &#8211; \u00c9tude: <a href=\"http:\/\/www.eurekalert.org\/pub_releases\/2015-09\/asoh-sbv092115.php\">Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients<\/a><\/p>\n<h1>&nbsp;<\/h1>\n","protected":false},"excerpt":{"rendered":"<p>Une \u00e9tude publi\u00e9e en juin 2015 dans le ASH Blood Journal, rapporte que le brentuximab vedotine s\u2019av\u00e8re un traitement de choix efficace et s\u00e9curitaire dans le cas de patients \u00e2g\u00e9s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17],"tags":[],"class_list":{"0":"post-2485","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-recherche"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"Une \u00e9tude publi\u00e9e en juin 2015 dans le ASH Blood Journal, rapporte que le brentuximab vedotine s\u2019av\u00e8re un traitement de choix efficace et s\u00e9curitaire dans le cas de patients \u00e2g\u00e9s...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2015-09-24T13:27:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin\",\"datePublished\":\"2015-09-24T13:27:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"articleSection\":[\"Recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\",\"name\":\"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"datePublished\":\"2015-09-24T13:27:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"width\":700,\"height\":300,\"caption\":\"masthead_ph_shadows\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/","og_locale":"fr_FR","og_type":"article","og_title":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada","og_description":"Une \u00e9tude publi\u00e9e en juin 2015 dans le ASH Blood Journal, rapporte que le brentuximab vedotine s\u2019av\u00e8re un traitement de choix efficace et s\u00e9curitaire dans le cas de patients \u00e2g\u00e9s...","og_url":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2015-09-24T13:27:23+00:00","og_image":[{"width":700,"height":300,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin","datePublished":"2015-09-24T13:27:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","articleSection":["Recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/","url":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/","name":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","datePublished":"2015-09-24T13:27:23+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","width":700,"height":300,"caption":"masthead_ph_shadows"},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/le-brentuximab-vedotine-chez-les-personnes-agees-atteintes-de-la-maladie-de-hodgkin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Le brentuximab vedotine chez les personnes \u00e2g\u00e9es, atteintes de la maladie de Hodgkin"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=2485"}],"version-history":[{"count":0,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2485\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/1771"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=2485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=2485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=2485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}